Successful drug development is increasingly dependent on a robust “fail fast” strategy that includes incorporation of safety/toxicology endpoints into lead optimization pharmacology studies.
Toronto, Canada (PRWEB) March 21, 2013
Successful drug development is increasingly dependent on a robust “fail fast” strategy that includes incorporation of safety/toxicology endpoints into lead optimization pharmacology studies. This early marriage of pharmacology and toxicology will provide insight into the margin of safety that is critical for advancing the molecule, the design of the good laboratory practice studies and the clinical plan.
This webinar will focus on lead optimization pharmacology and toxicology and a fail fast strategy that many companies are using. The advantages and disadvantages of incorporating safety and toxicology endpoints in pharmacology studies will be discussed along with case studies demonstrating their potential value.
For more information about this event or to register, visit: http://xtks.in/xto583-event.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about, Xtalks visit http://xtalks.com/ContactUs.ashx.
Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com
We're here to help.
Call 1-866-640-6397
©Copyright 1997-, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
